Dr. West on ALK-NSCLC Crizotinib Survival Benefit

H. Jack West, MD
Published: Thursday, Jun 30, 2011



H. Jack West, MD, medical director of the Thoracic Oncology Program at the Swedish Cancer Institute in Seattle, Washington discusses how crizotinib demonstrated a survival benefit in ALK-non-small cell lung cancer (NSCLC).

Dr. West says there is a survival benefit conferred by crizotinib, with the caveat that those patients who tested positive but didn't get NSCLC may have had some other issue that confounds the matter. Looking at the demographics and various other characteristics of the patient population, it seemed that they were similar. Yet, the patients who got crizotinib did far better than those who had an ALK rearrangement but didn't.


H. Jack West, MD, medical director of the Thoracic Oncology Program at the Swedish Cancer Institute in Seattle, Washington discusses how crizotinib demonstrated a survival benefit in ALK-non-small cell lung cancer (NSCLC).

Dr. West says there is a survival benefit conferred by crizotinib, with the caveat that those patients who tested positive but didn't get NSCLC may have had some other issue that confounds the matter. Looking at the demographics and various other characteristics of the patient population, it seemed that they were similar. Yet, the patients who got crizotinib did far better than those who had an ALK rearrangement but didn't.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 18th Annual International Lung Cancer Congress®Oct 31, 20181.5
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Publication Bottom Border
Border Publication
x